Zevra Therapeutics (ZVRA) Competitors $12.34 +0.78 (+6.75%) As of 11:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMYShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Vericel Agios Pharmaceuticals CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Vericel (NASDAQ:VCEL) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Which has more risk and volatility, VCEL or ZVRA? Vericel has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Does the media refer more to VCEL or ZVRA? In the previous week, Zevra Therapeutics had 11 more articles in the media than Vericel. MarketBeat recorded 13 mentions for Zevra Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.73 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VCEL or ZVRA? 35.0% of Zevra Therapeutics shares are held by institutional investors. 5.2% of Vericel shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is VCEL or ZVRA more profitable? Vericel has a net margin of 1.25% compared to Zevra Therapeutics' net margin of -226.78%. Vericel's return on equity of 1.09% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.25% 1.09% 0.73% Zevra Therapeutics -226.78%-201.05%-53.55% Which has stronger earnings & valuation, VCEL or ZVRA? Vericel has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M9.01$10.36M$0.031,415.33Zevra Therapeutics$23.61M28.58-$105.51M-$1.90-6.49 Do analysts recommend VCEL or ZVRA? Vericel currently has a consensus target price of $61.14, indicating a potential upside of 44.00%. Zevra Therapeutics has a consensus target price of $23.71, indicating a potential upside of 92.17%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryVericel beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$674.20M$2.43B$5.59B$9.00BDividend YieldN/A1.80%5.25%4.03%P/E Ratio-6.499.3627.5420.18Price / Sales28.58603.19415.83171.78Price / CashN/A161.3437.0657.97Price / Book16.684.658.105.61Net Income-$105.51M$31.26M$3.17B$248.59M7 Day Performance26.11%6.39%3.33%4.67%1 Month Performance32.97%3.65%3.54%7.18%1 Year Performance119.57%2.23%33.62%21.21% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.7637 of 5 stars$12.34+6.7%$23.71+92.2%+111.1%$674.20M$23.61M-6.4920News CoverageAnalyst ForecastVCELVericel2.9526 of 5 stars$41.79+0.8%$61.14+46.3%-9.9%$2.10B$237.22M1,393.30300AGIOAgios Pharmaceuticals4.0801 of 5 stars$36.06+2.0%$58.60+62.5%-8.5%$2.09B$36.50M3.21390CGONCG Oncology2.3802 of 5 stars$26.90+0.8%$58.67+118.1%-15.8%$2.05B$1.14M-17.8161KNSAKiniksa Pharmaceuticals International3.4517 of 5 stars$27.86+1.5%$38.80+39.3%+42.4%$2.03B$423.24M-111.42220Analyst ForecastBEAMBeam Therapeutics2.6711 of 5 stars$20.02+0.7%$48.75+143.5%-10.0%$2.01B$63.52M0.00510Gap UpIDYAIDEAYA Biosciences3.428 of 5 stars$22.09+0.8%$53.42+141.8%-40.5%$1.94B$7M-6.1580News CoverageAnalyst UpgradeIRONDisc Medicine3.1744 of 5 stars$54.75+3.0%$96.70+76.6%+18.9%$1.90BN/A0.0030Insider TradeBLTEBelite Bio2.6536 of 5 stars$59.74+5.2%$96.67+61.8%+30.4%$1.89BN/A0.0010News CoverageAnalyst RevisionCNTACentessa Pharmaceuticals2.5912 of 5 stars$14.34+4.3%$27.89+94.6%+43.3%$1.88B$6.85M0.00200HRMYHarmony Biosciences4.8222 of 5 stars$32.09-0.1%$53.63+67.1%-0.8%$1.85B$714.73M12.27200Positive News Related Companies and Tools Related Companies Vericel Alternatives Agios Pharmaceuticals Alternatives CG Oncology Alternatives Kiniksa Pharmaceuticals International Alternatives Beam Therapeutics Alternatives IDEAYA Biosciences Alternatives Disc Medicine Alternatives Belite Bio Alternatives Centessa Pharmaceuticals Alternatives Harmony Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.